A review of scientific studies in the efficacy and safety of stem cell therapies in canines.

Soon after the genesis of regenerative medicine as a field of human study, scientists have been interested in the application of stem cell therapies to companion animals. JangoPet continues this tradition in its mission to bring the best that science has to offer to improve the lives of our pets. 

Below is a brief compendium of studies showing the efficacy and safety of stem cell therapies in dogs, particularly for treatment of osteoarthritis. The list below is not comprehensive, but representative of the history of medical research in this area.

learn stem cell terminology

Most non-doctors won’t know many of the terms associated with stem cell biology.
To help you make sense of it all, we have compiled a glossary (click the button below).

Academic Studies Discussing STEM CELL THERAPIES IN DOGS

Effect of Adipose-Derived Mesenchymal Stem and Regenerative Cells on Lameness in Dogs with Chronic Osteoarthritis of the Coxofemoral Joints: A Randomized, Double-Blinded, Multicenter, Controlled Trial.
Black et al., Veterinary Therapeutics Vol. 8, No. 4 (2007). 

  • Study using autologous stromal vascular fraction (SVF).
  • SVF injected into the hip joints. 
  • 21 dogs in the study. 
  • Findings: “Overall, dogs with OA [osteoarthritis] of the coxofemoral joint that were treated with intraarticular injection of AD-MSCs demonstrated statistically significant improvement in lameness compared with a blinded, saline-injected control group and significant improvement over time from baseline.” 

Production of canine mesenchymal stem cells from adipose tissue and their application in dogs with chronic osteoarthritis of the humeroradial joints.
Guerico et al., Cell Biology International, 36: 189-194 (2012). 

  • Study using autologous adipose-derived stem cells (ADSC). 
  • ADSCs injected into the elbow joints.  
  • 4 dogs in the study. 
  • Findings: “OA [osteoarthritis] of the elbow joints improved with time, indicating significant potential for clinical use in the treatment of lameness, particularly when administered before the injury becomes severe.” 
  • Study using chondrogenic induced MSCs (ciMSCs) collected from the bloodstream of a horse (i.e., xenogeneic stem cells).
  • Chondrogenic-induced MSCs (ciMSCs) injected into the elbow joint. 
  • 6 dogs in the study. 
  • Findings: “The single intra-articular administration of equine ciMSCs to treat naturally occurring OA in dogs proved to be a well-tolerated treatment, which reduced lameness and pain according to the owner’s evaluations compared to a placebo treatment.” 

Controlled, blinded force platform analysis of the effect of intraarticular injection of autologous adipose-derived mesenchymal stem cells associated to PRGF-Endoret in osteoarthritic dogs.
Vilar et al., BMC Vet. Res. 9, 131 (2013). 

  • Study using autologous adipose-derived stem cells (ADSC).
  • ADSCs injected into the hip joint. 
  • 8 dogs in the study. 
  • Findings: “Although this study was limited to a small number of dogs with severe OA [osteoarthritis], MSC therapy was found to be an appropriate treatment for hip joints, in terms of its efficacy in objectively improving the dogs’ gait and ability to live a more normal life, and the absence of side effects.” 
  • Study using autologous adipose-derived stem cells (ADSC). 
  • ADSCs injected into the hip joint. 
  • 35 dogs in the study. 
  • Findings: “Functional limitation, range of motion (ROM), owner’s and veterinary investigator visual analogue scale (VAS), and patient’s quality of life improved from the first month up to six months. The aMSCs group obtained better results at 6 months. There were no adverse effects during the study.” 
  • Study using allogeneic adipose-derived stem cells (ADSC). 
  • ADSCs injected into elbow joints. 
  • 30 dogs in the study. 
  • Findings: “Intra-articular injection of AT-MSCs resulted in highly significant and sustained improvement in the condition of the patients. Lameness was ameliorated after 3 mo of treatment (data not shown) without any further medication and this improvement persisted at least during the 1-year survey. To our knowledge, this is the longest survey carried out with the largest patient population in the literature.” 


Regenerative medicine is ever-changing as researchers and doctors learn more about the exciting possibilities of stem-cell-based therapies. JangoPet is committed to leveraging the current state of knowledge to provide customers and veterinarians cutting-edge therapeutic options to help animals affected by the degenerative effects of aging. Click below to explore our current services or to contact us directly.